Substance / Medication

Haloperidol

Overview

Active Ingredient
haloperidol
RxNorm CUI
5093

Indications

Haloperidol tablets, USP are indicated for use in the management of manifestations of psychotic disorders. Haloperidol tablets, USP are indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol tablets, USP are effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol tablets, USP are also effective in the short-term tre

Labeler: REMEDYREPACK INC.Updated: 2026-02-16T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypic

Contraindications

When this intervention should not be used

Haloperidol tablets, USP are contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have Parkinson’s disease.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

63 trials linked to this intervention

63
Total Trials
5
Recruiting
21
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effect of quetiapine versus haloperidol on delirium severity in hospitalized adults: A systematic review and meta‑analysis.
Zainab Shiza, Fatima Eshal, Khalid Muhammad Salman et al. · Asian J Psychiatr · 2026
PMID: 41483728Meta-Analysis
Haloperidol for the treatment of delirium in ICU patients: a systematic review and meta‑analysis.
Zhao Yue, Wang Qing, Sun Biao et al. · Eur J Med Res · 2025
PMID: 40025536Meta-AnalysisFull text (PMC)
Haloperidol versus second-generation antipsychotics on the cognitive performance of individuals with schizophrenia and related disorders: pairwise meta-analysis of randomized controlled trials.
Baldez Daniel Prates, Biazus Tais Boeira, Rabelo-da-Ponte Francisco Diego et al. · Trends Psychiatry Psychother · 2025
PMID: 37463340Meta-Analysis
Major adverse cardiac events with haloperidol: A meta-analysis.
Garcia Michael Cristian, Anderson Mason, Li Michelle et al. · PLoS One · 2025
PMID: 40561150Meta-AnalysisFull text (PMC)
Haloperidol for the treatment of delirium in critically ill patients: an updated systematic review with meta-analysis and trial sequential analysis.
Andersen-Ranberg Nina Christine, Barbateskovic Marija, Perner Anders et al. · Crit Care · 2023
PMID: 37633991Meta-AnalysisFull text (PMC)
Haloperidol for preventing delirium in ICU patients: a systematic review and meta-analysis.
Marra A, Vargas M, Buonanno P et al. · Eur Rev Med Pharmacol Sci · 2021
PMID: 33629327Meta-Analysis
Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies.
Waku Isabelle, Magalhães Mylena S, Alves Camila O et al. · Eur J Neurosci · 2021
PMID: 33818841Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Haloperidol (substance)
SNOMED CT
386837002
UMLS CUI
C0018546
RxNorm CUI
5093
Labeler
REMEDYREPACK INC.

Clinical Data

This intervention maps to 6 entities in the Healos knowledge graph.

6
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
63
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.